fashion -WSS

fashion

author：fashion 2025-09-02 11:46:44 - browse：84846

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wikipedia

WSS

People can get long Covid without testing positive for virus: Study

Roche's accidental data boosts hopes for anti

Republicans love RFK Jr. What's that tell us about health in 2024?

How the first Native Hawaiian psychiatrist helped diversify medicine

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

AI generated plenty of interest at JPM but not a lot of trust

leisure time

fashion

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Activists slam private health insurers over coverage restrictions

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Wildfire smoke exposes gaps in outdoor worker protections

EU regulator recommends expanding Mounjaro approval to obesity

Drug repurposing or repositioning? The language matters

Francis Collins on trust in science and how Covid communications failed

23andMe had bad news about my health. I wish a person had delivered it

Copay coupons to count toward deductibles, after Biden court move

leisure time

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

DeSantis wants to import drugs. Biden’s FDA blasted his plan

My yearlong odyssey to get my son’s ADHD medication covered

My yearlong odyssey to get my son’s ADHD medication covered

Dewpoint Therapeutics lays off staff after losing partnerships

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

knowledge

knowledge

Wikipedia

hotspot